drugset
drugset / Trial / NCT07160725

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07160725 ↗

Phase 1/2 Recruiting 315 enrolled Bristol-Myers Squibb
RandomizedSequentialOpen-labelTreatment

Summary

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors

Timeline

Start
2025-10-15
Primary completion
2028-07-31
Completion
2028-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986517 Unknown — —

Indications

cancer